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Health Protection, Public Health England, London, UKAbstractIn October 2007, a governmental 3-year target to reduce
Clostridium difﬁcile infection (CDI) by 30%, with ﬁnancial penalties
levied for failure, was introduced in England. This target was met
within just 1 year, leading to speculation of ‘gaming’, with
hospitals empirically treating possible CDI in the absence of a
microbiological diagnosis, to avoid having to report conﬁrmed
cases. An analysis of aggregate mandatory data on levels of
testing for C. difﬁcile toxin showed little evidence of a fall in
testing during the steepest infection rate reductions, suggesting
that this was not a major factor in the decline in CDI.
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E-mail: sarah.gerver@phe.gov.ukEnhanced mandatory surveillance of Clostridium difﬁcile infection
(CDI) in England was initiated in 2007, whereby all C. difﬁcile
toxin-positive stool samples in patients aged 2 years had to be
reported to Public Health England (PHE) [1]. Furthermore,
aggregated quarterly laboratory data for the number of stool
examinations and C. difﬁcile toxin tests that have been per-
formed are also reported to PHE. In October 2007, acuteMicrobiol Infect 2015; 21: 850.e1–850.e4
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p://dx.doi.org/10.1016/j.cmi.2015.04.013Trusts (hospitals under the same management) were set a 3-
year target of reducing CDI by 30% between April 2008 and
April 2011, with ﬁnancial penalties levied for failure [2]. This
objective was achieved and exceeded by April 2009, with >60%
decline by April 2011 [3]. This dramatic decrease in reported
CDI led, anecdotally, to speculation that NHS acute Trusts had
employed ‘gaming’ to avoid ﬁnancial penalties, possibly by
empirically treating likely cases of CDI without seeking micro-
biological conﬁrmation of the diagnosis (which if positive would
have been reportable), and that this, rather than better infec-
tion control practices or improved antimicrobial prescribing
practices, had caused the observed reduction in CDI. This study
sought to explore whether there was any evidence to
corroborate such concerns.
Aggregate mandatory laboratory data on stool examinations
and C. difﬁcile toxin testing for all NHS acute Trusts in England
for 2008–2013 were extracted from the English healthcare-
associated infections database [3], along with patient-level
CDI data for the same time period. National-level rates of
stool examination, C. difﬁcile toxin testing and CDI per 100 000
bed-days were calculated using the KH03 national dataset,
which gives the daily average overnight bed occupation in
Trusts [4]. KH03 provides a measure of clinical activity in each
Trust, which can be used as a proxy measure of the patient
population. These data were examined to ascertain whether
there had been a reduction in reported testing levels. Trends in
the relationships between C. difﬁcile toxin testing, stool exam-
inations and CDI cases were also examined, including calcu-
lating the expected rate of CDI for 2008–2013 based on the
2008 C. difﬁcile toxin tests to CDI ratio. Analyses were un-
dertaken using STATA 13.1 [5].
Although all NHS acute Trusts in England are mandated to
report quarterly laboratory data, 16 (10.1%) of 159 acute
Trusts had missing/incomplete data on stool samples or toxin
tests for at least one quarter between January 2008 and
December 2013 and were excluded from all analyses, leaving
143 acute Trusts.
The rate of CDI decreased by almost two-thirds between
2008 and 2013 (107.2/100 000 bed-days versus 40.0/100 000
bed-days, respectively), with 62.8% of the reductions occurring
between 2008 and 2010 (Fig. 1). There was an overall 16.2%
decline in the rate of C. difﬁcile toxin testing (1810.8/100 000
bed-days in 2008 versus 1517.5/100 000 bed-days in 2013);
however, a 1.5% year-on-year increase did occur between 2008
and 2010 (the time period for Trusts to meet the CDI target),
so declines in testing actually occurred post-2010. Had CDI
been directly related to C. difﬁcile toxin testing, we would have
expected a year-on-year increase until 2010, with a decrease
thereafter (Fig. 2). Unlike the infection and toxin testing rates,f of European Society of Clinical Microbiology and Infectious Diseases. All rights reserved
FIG. 1. Rate of C. difﬁcile toxin testing, stool examinations and C. difﬁcile infections per year: 2008–2013. The Clostridium difﬁcile infection rates are for
all-reported cases of C. difﬁcile and not those that are Trust-apportioned [11]. This is because the stool examinations and C. difﬁcile toxin test data
cannot be stratiﬁed to the same granularity achievable with patient-level C. difﬁcile infection data, which includes knowing the individual date of
specimen and date of admission to an acute Trust for each case. To be consistent when comparing rates of stool examinations, C. difﬁcile toxin tests and
C. difﬁcile infections, occupied bed-days were used as the denominator for all rate calculations. Data are from the 143 acute Trusts with complete
quarterly laboratory data only.
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increase of 4.9% from 4168.8/100 000 bed-days in 2008 to
4374.3/100 000 bed-days in 2013, with a peak in 2012 (4685.3/
100 000 bed-days). The ratio of both stool examinations and
C. difﬁcile toxin tests to the number of CDI cases increased overFIG. 2. Comparison of expected and observed rates of C. difﬁcile infections p
(CDI) per 100 000 bed-days was calculated using the ratio between C. difﬁcile to
toxin tests for each C. difﬁcile infection) remained the same for the following 5 ye
Crown Copyright © 2015 Clinical Microbiology and Infection published by Elsevier Ltd on behalftime, from 38.9 stool examinations per case in 2008 to 109.3 in
2013 and from 16.9 C. difﬁcile toxin tests per case in 2008 to
37.9 in 2013. By contrast, the ratio of stool examinations to
C. difﬁcile toxin tests increased only slightly from 2.3 in 2008 to
2.9 in 2013 (Table 1).er year: 2008–2013. The expected rate of Clostridium difﬁcile infections
xin tests and C. difﬁcile infections as observed in 2008 (i.e. 16.9 C. difﬁcile
ars (2009–2013). This has been plotted against the observed rate of CDI.
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TABLE 1. Counts and ratios between stool examinations, C. difﬁcile toxin tests and C. difﬁcile infections per year: 2008–2013
Year
Total number
of stool
examinations
Total number
of C. difﬁcile
toxin tests
Total number of
C. difﬁcile infections
Number of stool
examinations
performed per
C. difﬁcile toxin testa
Number of C. difﬁcile
toxin tests performed
per C. difﬁcile infection
Number of stool
examinations performed
per C. difﬁcile infection
2008 1 433 800 622 791 36 875 2.3 16.9 38.9
2009 1 453 657 631 926 25 087 2.3 25.2 57.9
2010 1 495 390 641 301 21 179 2.3 30.3 70.6
2011 1 442 453 581 713 17 500 2.5 33.2 82.4
2012 1 480 454 542 351 13 671 2.7 39.7 108.3
2013 1 376 834 477 623 12 594 2.9 37.9 109.3
aThe total number of stool examinations includes the number of stool samples taken for C. difﬁcile toxin testing.
850.e3 Clinical Microbiology and Infection, Volume 21 Number 9, September 2015 CMIThe testing protocol for CDI has been in ﬂux since 2009
after ESCMID reported that C. difﬁcile toxin enzyme immuno-
assays were suboptimal as a stand-alone diagnostic test and
recommended a two-step testing protocol [6], with toxin
testing performed as the second-step only if the ﬁrst-step
(detection of glutamate dehydrogenase) was positive. In
March 2012 new guidance was published on the diagnosis and
reporting of CDI in England [7]. Before the publication of these
guidelines, the majority of NHS laboratories used a stand-alone
C. difﬁcile toxin enzyme immunoassay to diagnose CDI [8];
however, between September 2012 and August 2013, 49 (94%)
of 52 hospitals in England queried, reported using the optimized
diagnostic testing algorithm for CDI [9]. Therefore, this change
in testing protocol for CDI may partially explain the decline in
toxin testing from 2010, as subsequent testing would have been
restricted to conﬁrmation of putatively positive cases. How-
ever, the new guidance issued in 2012 for CDI diagnostic
testing contained no recommendations for the reporting of
C. difﬁcile testing data, hence there is uncertainty as to whether
Trusts have reported C. difﬁcile toxin testing exclusively or any
diagnostic investigations of suspected CDI. As the laboratory
data are aggregate-level and lack demographic details, it is not
possible to distinguish whether decreases in toxin testing have
occurred in all patients similarly or are predominantly among
particular groups (i.e. patients 65 years). In addition, this also
precludes the ability to consider if the testing of patients
suffering recurrent CDI has decreased over time, as has been
suggested by clinicians [10]. Cases empirically treated and not
tested/reported as CDI could cause a disproportionate reduc-
tion in CDI numbers versus numbers tested. However, this
would rely on the empirically treated sample predominantly
being positive cases, requiring substantial knowledge of the
patients’ history to reliably select. To determine if, or the
extent to which, this occurred it would be necessary to
correlate the number of patients treated for CDI with the
number of reported CDI. However, prescribing data are not
readily available on a national scale to allow for such an analysis.
Despite these caveats it should be noted that these data are theCrown Copyright © 2015 Clinical Microbiology and Infection published by Elsevier Ltd on behalf
CMI, 21, 850.e1–850.e4only national-level data available regarding testing for CDI with
a paucity of comparable data worldwide.
In conclusion, while there has been an overall decline in the
count and rate of C. difﬁcile toxin testing performed in England
since 2008, there has been a much greater reduction in CDI,
resulting in a much higher ratio of toxin tests performed per
case of CDI in 2013 than in 2008. In addition, there was an
increase in the counts and rates of both stool examinations and
C. difﬁcile toxin tests between 2008 and 2010, when the ma-
jority of the large decline observed in CDI in England occurred.
Together, this suggests that there is little evidence of large-scale
changes in testing practices or that ‘gaming’ by NHS Trusts to
avoid exceeding their CDI targets and incurring ﬁnancial pen-
alties, was not a major factor in the reduction of CDI in
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